- Home
- DBD vs VCEL Comparison
DBD vs VCEL Comparison
Compare DBD & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBD
- VCEL
- Stock Information
- Founded
- DBD 1859
- VCEL 1989
- Country
- DBD United States
- VCEL United States
- Employees
- DBD N/A
- VCEL N/A
- Industry
- DBD EDP Services
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DBD Technology
- VCEL Health Care
- Exchange
- DBD Nasdaq
- VCEL Nasdaq
- Market Cap
- DBD 2.2B
- VCEL 2.1B
- IPO Year
- DBD N/A
- VCEL 1997
- Fundamental
- Price
- DBD $61.28
- VCEL $36.50
- Analyst Decision
- DBD Strong Buy
- VCEL Strong Buy
- Analyst Count
- DBD 2
- VCEL 7
- Target Price
- DBD $75.00
- VCEL $61.29
- AVG Volume (30 Days)
- DBD 215.1K
- VCEL 552.7K
- Earning Date
- DBD 08-06-2025
- VCEL 07-31-2025
- Dividend Yield
- DBD N/A
- VCEL N/A
- EPS Growth
- DBD N/A
- VCEL 2045.40
- EPS
- DBD N/A
- VCEL 0.13
- Revenue
- DBD $3,672,300,000.00
- VCEL $249,119,000.00
- Revenue This Year
- DBD $3.09
- VCEL $18.35
- Revenue Next Year
- DBD $2.74
- VCEL $22.47
- P/E Ratio
- DBD N/A
- VCEL $267.31
- Revenue Growth
- DBD N/A
- VCEL 16.13
- 52 Week Low
- DBD $34.88
- VCEL $33.09
- 52 Week High
- DBD $63.46
- VCEL $63.00
- Technical
- Relative Strength Index (RSI)
- DBD 62.36
- VCEL 46.52
- Support Level
- DBD $62.12
- VCEL $35.18
- Resistance Level
- DBD $63.46
- VCEL $36.87
- Average True Range (ATR)
- DBD 1.21
- VCEL 1.32
- MACD
- DBD 0.05
- VCEL 0.13
- Stochastic Oscillator
- DBD 73.83
- VCEL 45.47
About DBD Diebold Nixdorf Incorporated Common stock
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment. Geographically, the company generates maximum revenue from Europe, Middle East, and Africa (EMEA), followed by the Americas and the Asia-Pacific region.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.